

# Teppeï Sugano

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1251752/publications.pdf>

Version: 2024-02-01

23  
papers

394  
citations

840585

11  
h-index

794469

19  
g-index

25  
all docs

25  
docs citations

25  
times ranked

553  
citing authors

#	ARTICLE	IF	CITATIONS
1	A Novel Molecular Target in <i>EGFR</i> -mutant Lung Cancer Treated With the Combination of Osimertinib and Pemetrexed. <i>Anticancer Research</i> , 2022, 42, 709-722.	0.5	6
2	Carboplatin plus nanoparticle albumin-bound paclitaxel for the treatment of thymic carcinoma. <i>Molecular and Clinical Oncology</i> , 2022, 16, 87.	0.4	3
3	Pharmacological blockage of transforming growth factor- $\beta$ signalling by a Traf2- and Nck-interacting kinase inhibitor, NCB-0846. <i>British Journal of Cancer</i> , 2021, 124, 228-236.	2.9	17
4	Direct conversion of osteosarcoma to adipocytes by targeting TNK1. <i>JCI Insight</i> , 2021, 6, .	2.3	12
5	Successful Treatment with Afatinib after Osimertinib-induced Interstitial Lung Disease in a Patient with <i>EGFR</i> -mutant Non-small-cell Lung Cancer. <i>Internal Medicine</i> , 2021, 60, 591-594.	0.3	6
6	Long Non-Coding RNA CRNDE Is Involved in Resistance to <i>EGFR</i> Tyrosine Kinase Inhibitor in <i>EGFR</i> -Mutant Lung Cancer via eIF4A3/MUC1/ <i>EGFR</i> Signaling. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4005.	1.8	24
7	Exosome-derived <i>miR-210</i> involved in resistance to osimertinib and epithelial-mesenchymal transition in <i>EGFR</i> mutant non-small cell lung cancer cells. <i>Thoracic Cancer</i> , 2021, 12, 1690-1698.	0.8	29
8	PD-L1 Expression Status Predicting Survival in Pulmonary Pleomorphic Carcinoma. <i>Anticancer Research</i> , 2021, 41, 2501-2509.	0.5	1
9	Clinicopathological characteristics of kidney injury in non-small cell lung cancer patients under combination therapy including pembrolizumab. <i>CEN Case Reports</i> , 2021, , 1.	0.5	2
10	Immune checkpoint inhibitor-associated interstitial lung diseases correlate with better prognosis in patients with advanced non-small-cell lung cancer. <i>Thoracic Cancer</i> , 2020, 11, 1052-1060.	0.8	36
11	Prognostic impact of <i>ACTN4</i> gene copy number alteration in hormone receptor-positive, HER2-negative, node-negative invasive breast carcinoma. <i>British Journal of Cancer</i> , 2020, 122, 1811-1817.	2.9	8
12	Weekly paclitaxel in combination with carboplatin for advanced non-small-cell lung cancer complicated by idiopathic interstitial pneumonias: a single-arm phase II study. <i>International Journal of Clinical Oncology</i> , 2019, 24, 1543-1548.	1.0	16
13	Intralymphatic histiocytosis in a patient with lung adenocarcinoma treated with pembrolizumab: a case report. , 2019, 7, 59.		9
14	Interstitial lung disease associated with nanoparticle albumin-bound paclitaxel treatment in patients with lung cancer. <i>Japanese Journal of Clinical Oncology</i> , 2019, 49, 165-173.	0.6	17
15	A Case of Metastasis to Ovarian Tumor from Pulmonary Large-cell Neuroendocrine Carcinoma. <i>Japanese Journal of Lung Cancer</i> , 2019, 59, 88-93.	0.0	0
16	Pembrolizumab and salvage chemotherapy in <i>EGFR</i> T790M-positive non-small-cell lung cancer with high PD-L1 expression. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 5601-5605.	1.0	7
17	A case of interstitial lung disease with alveolar hemorrhage induced by pembrolizumab. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 5879-5883.	1.0	10
18	Pembrolizumab-induced agranulocytosis in a pulmonary pleomorphic carcinoma patient who developed interstitial lung disease and ocular myasthenia gravis. <i>Oxford Medical Case Reports</i> , 2018, 2018, omy094.	0.2	23

#	ARTICLE	IF	CITATIONS
19	miR-200/ZEB axis regulates sensitivity to nintedanib in non-small cell lung cancer cells. <i>International Journal of Oncology</i> , 2016, 48, 937-944.	1.4	66
20	MET FISH-positive status predicts short progression-free survival and overall survival after gefitinib treatment in lung adenocarcinoma with EGFR mutation. <i>BMC Cancer</i> , 2015, 15, 31.	1.1	29
21	Control of the MYC-eIF4E axis plus mTOR inhibitor treatment in small cell lung cancer. <i>BMC Cancer</i> , 2015, 15, 241.	1.1	16
22	Inhibition of ABCB1 Overcomes Cancer Stem Cell-like Properties and Acquired Resistance to MET Inhibitors in Non-small Cell Lung Cancer. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 2433-2440.	1.9	51
23	Significance of osteopontin in the sensitivity of malignant pleural mesothelioma to pemetrexed. <i>International Journal of Oncology</i> , 2014, 44, 1886-1894.	1.4	6